Express News | Xiamen Amoytop Biotech: The company will donate 9 million yuan to the China Hepatitis Prevention and Control Foundation for public welfare projects aimed at preventing liver cancer in high-risk groups related to hepatitis B virus.

BreakingsMar 7 19:21

Can Xiamen Amoytop Biotech, with a market cap of over 30 billion, continue to acquire assets and replicate its wealth?

Looking to grasp the third turning point. According to Cai Jun from Xiamen Amoytop Biotech (688278.SH, hereinafter referred to as the "Company"), the search for the next explosive product is underway. Recently, the Company announced a cross-industry acquisition. Since 2023, the Company has made a total of three purchases/acquisitions related to pipelines and Assets. Unlike the previous two transactions, this acquisition involves a higher amount. Since its establishment, the Company has captured two key turning points. These include both the efforts of the technical team and the gifts of the times. Now, the Company aims to seize the third turning point. Whether it can make another leap will determine its future development. The first turning point was in the 1990s.

China InvestorsMar 2 08:01

Tebao Biotech: Tepo Biotech: 2024 Annual Results Report Announcement

SZSIFeb 26 00:00 · Announcements

Tebao Biotech: 2024 Annual Results Report Announcement

SZSIFeb 26 00:00 · Announcements

Xiamen Amoytop Biotech (688278.SH): The net income for the fiscal year 2024 is 0.828 billion yuan, an increase of 49.00% year-on-year.

Gelonghui, February 25th丨Xiamen Amoytop Biotech (688278.SH) announced its 2024 annual performance report. During the reporting period, the company's operating performance maintained steady growth, achieving a total operating income of 2.817 billion yuan, a year-on-year increase of 34.13%; achieving a net income attributable to the parent company's owners of 0.828 billion yuan, a year-on-year increase of 49.00%; achieving a net income attributable to the parent company's owners after deducting non-recurring gains and losses of 0.827 billion yuan, a year-on-year increase of 42.73%. During the reporting period, the company’s main business remained robust, particularly as the clinical cure research for hepatitis B continued to deepen, the company's product Pegasys, as a chronic

Gelonghui FinanceFeb 25 16:36

Xiamen Amoytop Biotech to Acquire Skyline Therapeutics Assets for $15 Million

MT NewswiresFeb 25 15:50